B
CTNM

Bailard’s Contineum Therapeutics CTNM Stock Holding History

Bailard’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,350
Closed -$145K – 895
2025
Q3 		$145K Buy
+12,350
New +$99.6K ﹤0.01% 749

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bailard's CTNM Position: Q4 2025 in Review

Bailard sold out of Contineum Therapeutics (CTNM) in Q4 2025, closing a stake of 12,350 shares — an estimated $145K sold.

Bailard first reported a position in CTNM in Q3 2025 and held it in 1 quarter. The position peaked at $145K in Q3 2025. 80 funds tracked by Wall St. Rank hold CTNM as of Q4 2025.

  • Bailard reported no remaining Contineum Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Bailard sold 12,350 Contineum Therapeutics shares in Q4 2025, an estimated $145K.
  • Bailard first reported a position in Contineum Therapeutics in Q3 2025 and held it in 1 quarter.
  • Bailard's Contineum Therapeutics position peaked at $145K in Q3 2025.
  • 80 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q4 2025.

Based on Bailard's 13F filing for Q4 2025, filed 4 Feb 2026.